We successfully represented Janssen in this action for damages resulting from infringement of the patent covering Janssen’s LEVAQUIN product. Following a two week trial, the Federal Court agreed that Janssen’s U.S. affiliate had standing to sue for patent infringement and awarded damages in excess of $18 Million. Teva appealed on every issue. The Court of Appeal affirmed (2018 FCA 33).